Mycophenolate mofetil for ocular myasthenia
- 29 February 2008
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Zeitschrift für Neurologie
- Vol. 255 (4), 510-513
- https://doi.org/10.1007/s00415-008-0718-9
Abstract
To study the safety and tolerability of mycophenolate mofetil (MM), since this steroid-sparing immunomodulatory agent with less side effects, compared to corticosteroids, may be considered for long-term management of ocular myasthenia (OMG). Consecutive patients with OMG started on MM between December 2000 and December 2002 were followed up to December 2006. All of the 31 patients with OMG were treated with prednisone at 40-60 mg/d while MM was increased up to the target of 1.0 g/d. After symptoms completely resolved, all patients were then tapered off prednisone over a period of 4 weeks. Eighty-seven percent (27/31) of patients continued on MM during the study. Mycophenolate mofetil discontinuation occurred in 4/31 (13%) of patients within the first four months of starting the drug. Of the patients who continued on MM, 93% (25/27) remained at stage I of the disease. The 7% (2/27) of patients on MM who generalized in our study did so by 2 years and were treated with additional prednisone. MM-related adverse events included nausea in 9 of 31 patients, diarrhea in 5 of 31 patients, and vomiting in 1/31 patients. No cases of infections, cytopenias, or malignancies were observed. Eighty-seven percent of OMG patients on corticosteroids who were switched to MM remained at Stage I of the disease over a mean period of 4.2 years. MM at 1.0 g/d was safe and tolerable as a long-term immunosuppressant for OMG.This publication has 10 references indexed in Scilit:
- Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease?Journal of the Neurological Sciences, 2004
- The effect of prednisone on the progression from ocular to generalized myasthenia gravisJournal of the Neurological Sciences, 2004
- Mycophenolate mofetil for myasthenia gravisNeurology, 2003
- Mycophenolate mofetil for myasthenia gravis: An open-label pilot studyNeurology, 2001
- Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseasesNeurology, 2001
- Myasthenia gravisNeurology, 2000
- Ocular myasthenia gravis: response to long-term immunosuppressive treatment.Journal of Neurology, Neurosurgery & Psychiatry, 1997
- The natural course of myasthenia gravis: a long term follow up study.Journal of Neurology, Neurosurgery & Psychiatry, 1989
- Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.Journal of Neurology, Neurosurgery & Psychiatry, 1985
- Prognosis of ocular myastheniaAnnals of Neurology, 1983